Chiral Recognition in the S_N2 Reaction of t-Butyl 2-Bromopropionate with the Enolate Derived from [(η⁵-C₅H₅)Fe(CO)(PPh₃)COCH₃]


Stephen P. Collingwood, Stephen G. Davies* and Simon C. Preston

The Dyson Perrins Laboratory, South Parks Road, Oxford, OX1 3QY, U.K.


Abstract: The lithium enolate derived from the homochiral iron acetyl complex S-[$(\eta^{5}-C_{5}H_{5})$ -Fe(CO)(PPh₃)COCH₃] reacts preferentially (40:1) with the R-enantiomer of racemic t-butyl 2-bromopropionate.

Homochiral α -alkyl succinic acid derivatives are key building blocks of many pharmacologically active molecules. Recent reports have described pseudopeptides displaying antibiotic,¹ anticancer² and enzyme inhibitory properties.³ We recently communicated two methods for the asymmetric synthesis of differentially protected homochiral α -alkyl succinic acid derivatives using the iron chiral auxiliary [(η^{5} -C₅H₅)Fe(CO)(PPh₃)]: the reaction of chiral ester enolate equivalents with bromoacetates⁴ and the alkylation of a chiral succinate enolate equivalent.^{5,6} We now report that the enolate of the iron acetyl complex (η^{5} -C₅H₅)Fe(CO)(PPh₃)COCH₃ (1) exhibits remarkable chiral discrimination in its S_N2 reaction with t-butyl 2-bromopropionate to give an iron 3-methylsuccinoyl complex of high diastereoisomeric purity.

Deprotonation of the racemic iron acetyl complex R,S-1 with butyllithium at -78°C in tetrahydrofuran followed by treatment with racemic t-butyl 2-bromopropionate gave a 40:1 mixture (>95% d.e.) of the succinoyl complexes RS,SR-2 and RR,SS-3. The yield was only moderate (29%) owing to decomposition *via* competitive debromination of the α -bromoester. The selectivity represents the degree of chiral discrimination between the enantiomers of the iron acetyl enolate and those of the α -bromoester, and is an order of magnitude superior to that previously obtained by methylation of the unsubstituted succinoyl complex.⁶ The major diastereoisomer was isolated pure by crystallisation and a single crystal X-ray structure analysis established the relative configuration between the iron and β -carbon centres as RS,SR.⁷



The proposed origin of the above chiral discrimination phenomenon is shown in the Figure. Lithium chelation between the enolate oxygen and the ester carbonyl delivers the α -carbon of the ester over the enolate in the correct orientation for the S_N2 displacement. For the mismatched R-enolate and R-bromoester this delivery involves a significant steric interaction of the α -methyl group and the cyclopentadienyl ligand. Such a destabilising interaction is absent in the R-enolate, S-bromoester matched combination. Consistent with the proposed importance of lithium chelation, repetition of the alkylation in the presence of HMPA resulted in a diminution of the diastereoselectivity to 6:1.



R-iron + S-bromo ester

R-iron + R-bromo ester

Figure : Matched and unmatched transition states

Homochiral SR-2 was obtained in 95% d.e. from the reaction of the enolate of homochiral S-1 with ten equivalents of racemic t-butyl 2-bromopropionate. The complex could be obtained diastereoisomerically and enantiomerically pure by column chromatography $\{[\alpha]_D^{20} -49.4 (c \ 0.235, C_6H_6)\}$. Reaction of the enolate of homochiral R-1 with homochiral S-t-butyl 2-bromopropionate gave homochiral RS-2 as a single diastereoisomer whereas reaction of the enolate of S-1 with S-t-butyl 2-bromopropionate gave a 50:50 mixture of SR-2 and SS-3. These results demonstrate that the reaction is S_N^2 in character. Furthermore the latter result implies that S-t-butyl 2-bromopropionate is racemised by liberated bromide ion faster than it reacts with the S-iron enolate under the reaction conditions employed.

The use of complexes such as 2 as homochiral differentially protected succinic acid derivatives has been previously established.⁴⁻⁶ Furthermore the chiral discrimination appears to be general, for example, d.e.s of >50:1 were observed for RCH(Br)CO₂^tBu, R = Et (37%), ⁱBu(30%) and the yield could be improved by utilisation of the triflate as leaving group, e.g. R = iBu(46%) without compromising the selectivity.

We thank British Biotechnology Ltd. and the S.E.R.C. for support.

References:

1. J.J. Gordon, J.P. Devlin, A.J. East, W.D. Ollis, I.O. Sutherland, D.E. Wright and L. Ninet, J. Chem. Soc., Perkin Trans I, 1975, 819.

2. R.Reich, E.W. Thompson, Y. Iwamoto, G.R. Martin J.R. Deason, G.C. Fuller and R. Miskin, *Cancer Res.*, 1988, 48, 3307.

3. H. Umezawa, T. Aoyagi, T. Tanake, H. Suda, A. Okuyama, O. Hiroyuki, M. Hamada and T. Takeuchi, J. Antibiot., 1985, 38, 1629; M.Hachisu, T. Hiranuma, Y. Shibazaki, K. Uotani, S. Murata, T. Aoyagi and H. Umezawa, Eur. J. Pharm., 1987, 137, 59; M. Hachisu, T. Hiranuma, S. Murata, T. Aoyagi and H. Umezawa, Life Sci., 1987, 41, 235.

4. G. Bashiardes, S.P. Collingwood, S.G. Davies and S.C. Preston, J. Organomet. Chem., 1989, 364, C29.

5. G. Bashiardes and S.G. Davies, Tetrahedron Lett., 1988, 29, 6509.

6. G. Bashiardes, S.P. Collingwood, S.G. Davies and S.C. Preston, J. Chem. Soc., Perkin I, 1989, 1162.

7. S.G. Davies and M. Wills, unpublished results.

(Received in UK 18 April 1990)